Brazil’s public healthcare system, the SUS (Sistema Único de Saúde), is expanding access to the antibiotic doxycycline as a preventative measure against sexually transmitted infections (STIs) – specifically, syphilis and chlamydia. The move, announced this week, marks a significant step in the country’s public health strategy to combat rising STI rates and reduce the burden of these often-treatable infections.
The Ministry of Health published a decree on March 13, 2026, formalizing the use of doxycycline 100mg as post-exposure prophylaxis (PEP) for these bacterial STIs. This means the antibiotic will be offered to individuals following potential exposure, such as after unprotected sexual intercourse. The decision follows approval by the National Commission for the Incorporation of Technologies in the Unified Health System (Conitec), signaling a commitment to evidence-based preventative care.
What are Syphilis and Chlamydia?
Syphilis, caused by the bacterium Treponema pallidum, is a curable STI that can manifest in various stages if left untreated. Transmission occurs primarily through sexual contact – oral, vaginal, or anal – especially when lesions are present and without the use of a condom. Vertical transmission, from a pregnant person to their baby during gestation or childbirth, is also a concern. According to the Ministry of Health, syphilis is exclusive to humans.
Chlamydia, another common bacterial STI, frequently infects the genital organs but can also affect the throat and eyes. It impacts both men and women who are sexually active. Transmission occurs through sexual contact – anal, oral, or vaginal – or congenitally from mother to baby during pregnancy. Importantly, the Ministry of Health clarifies that chlamydia is not transmitted through blood transfusions, though individuals with an infection should inform healthcare professionals if they wish to donate blood.
How Will the Latest Protocol Work?
The implementation of this new preventative measure will occur in phases. The Ministry of Health has allotted a maximum of 180 days for technical areas within the SUS to fully integrate the doxycycline PEP into the system. Specific guidelines for administration – including which populations will be prioritized and under what circumstances the prophylaxis will be indicated – will be detailed in updated Clinical Protocols and Therapeutic Guidelines.
Doxycycline works by inhibiting bacterial protein synthesis, effectively preventing the bacteria from multiplying. When administered shortly after potential exposure, it can eliminate the bacteria before an infection takes hold. This approach, PEP, is already utilized in other public health contexts, such as HIV prevention after a risk exposure.
Impact and Future Steps
This expansion of doxycycline’s use represents a proactive shift in Brazil’s approach to STI control. By offering preventative treatment, the SUS aims to reduce the incidence of these infections, alleviate the strain on healthcare resources and improve public health outcomes. The Ministry of Health emphasizes the importance of early detection and treatment for both syphilis and chlamydia, as these infections can have serious long-term health consequences if left unaddressed.
The next step will be the development and dissemination of clear guidelines for healthcare providers across the SUS network, ensuring consistent and effective implementation of the new protocol. Monitoring the impact of this initiative – tracking STI rates and assessing the effectiveness of doxycycline PEP – will be crucial in evaluating its long-term success.
This is a developing story. Share your thoughts in the comments below, and please share this article with your network.
Disclaimer: This article provides informational content about public health initiatives and is not intended to be a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.
